Prexige TARGET Study: Not Quite A Bull’s-Eye For Novartis

 
• By The Pink Sheet

Novartis' TARGET study found that the COX-2 inhibitor Prexige has approximately one-third the rate of gastrointestinal side effects compared to non-steroidal anti-inflammatory drugs

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Pink Sheet